Drug General Information
Drug ID	D08FMK
Former ID	DIB005526
Drug Name	LY2944876
Indication	Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1]		Phase 2	[524727]
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Glucagon-like peptide 1 receptor	Target Info	Modulator	[1572591]
	Glucagon receptor	Target Info	Modulator	[1572591]
KEGG Pathway	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Insulin secretionhsa04080:Neuroactive ligand-receptor interaction
	Glucagon signaling pathway
Reactome	Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
	G alpha (s) signalling events
	Glucagon-type ligand receptorsR-HSA-163359:Glucagon signaling in metabolic regulation
	G alpha (q) signalling events
	Glucagon-type ligand receptors
WikiPathways	GPCRs, Class B Secretin-like
	Integration of energy metabolism
	GPCR ligand binding
	GPCR downstream signalingWP334:GPCRs, Class B Secretin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	GPCR downstream signaling
References
Ref 524727	ClinicalTrials.gov (NCT02119819) A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes. U.S. National Institutes of Health.
Ref 1572591	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.